Zoetis (ZTS) Stock Forecast & Price Target

Compare

3,836 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZTS Analyst Ratings

Moderate Buy

6 Buy

6 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Zoetis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZTS Stock 12 Month Forecast

Average Price Target

$148.20

▲(21.55% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $148.20 with a high forecast of $200.00 and a low forecast of $130.00. The average price target represents a 21.55% change from the last price of $121.93.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","201":"$201","143.25":"$143.3","162.5":"$162.5","181.75":"$181.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$148.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,143.25,162.5,181.75,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.285,131.03230769230768,136.77961538461537,142.52692307692308,148.27423076923077,154.02153846153846,159.76884615384614,165.51615384615383,171.26346153846154,177.01076923076923,182.7580769230769,188.50538461538463,194.2526923076923,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.285,127.0476923076923,128.8103846153846,130.5730769230769,132.33576923076922,134.09846153846152,135.86115384615385,137.62384615384616,139.38653846153846,141.14923076923077,142.91192307692307,144.67461538461538,146.43730769230768,{"y":148.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,125.285,125.64769230769231,126.01038461538461,126.37307692307692,126.73576923076922,127.09846153846154,127.46115384615385,127.82384615384615,128.18653846153845,128.54923076923077,128.91192307692307,129.27461538461537,129.6373076923077,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":160.109,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.449,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.841,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.588,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.935,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.554,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.436,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.244,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.194,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.817,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.477,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.708,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.285,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$148.20

Lowest Price Target$130.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Ryskin

Bank of America Securities

$135

Hold

10.72%

Upside

Reiterated

01/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Zoetis (NYSE: ZTS) and Resmed (NYSE: RMD)

Andrea Alfonso

UBS

$141→$136

Hold

11.54%

Upside

Reiterated

01/29/26

Zoetis price target lowered to $136 from $141 at UBSZoetis price target lowered to $136 from $141 at UBS

David Westenberg

Piper Sandler

$190→$135

Hold

10.72%

Upside

Downgraded

01/22/26

Zoetis downgraded to Neutral from Overweight at Piper SandlerZoetis downgraded to Neutral from Overweight at Piper Sandler

Jonathan Block

Stifel Nicolaus

$140→$130

Hold

6.62%

Upside

Reiterated

01/15/26

Zoetis (ZTS) Gets a Hold from Stifel Nicolaus

Erin Wright

Morgan Stanley

$175→$160

Buy

31.22%

Upside

Reiterated

12/18/25

Zoetis price target lowered to $160 from $175 at Morgan StanleyZoetis price target lowered to $160 from $175 at Morgan Stanley

Sidharth Sahoo

HSBC

$180→$140

Buy

14.82%

Upside

Reiterated

12/10/25

Zoetis price target lowered to $140 from $180 at HSBCZoetis price target lowered to $140 from $180 at HSBC

Glen Santangelo

Barclays

$136

Hold

11.54%

Upside

Initiated

12/08/25

Zoetis initiated with an Equal Weight at BarclaysZoetis initiated with an Equal Weight at Barclays

Steve Scala

TD Cowen

$189→$150

Buy

23.02%

Upside

Reiterated

12/03/25

TD Cowen Reaffirms Their Buy Rating on Zoetis (ZTS)

Mark Massaro

BTIG

$160

Buy

31.22%

Upside

Reiterated

12/03/25

Zoetis Positioned for Long-Term Growth with Strategic Market Expansion and Innovative Product Launches

Brandon Vazquez

William Blair

Buy

―

Reiterated

12/02/25

Zoetis: Strong Innovation Pipeline and Attractive Valuation Justify Buy Rating Despite Near-Term Challenges

Steve Dechert

KeyBanc

Hold

―

Initiated

11/20/25

Zoetis initiated with a Sector Weight at KeyBancZoetis initiated with a Sector Weight at KeyBanc

Chris Schott

J.P. Morgan

$200

Buy

64.03%

Upside

Assigned

11/05/25

Zoetis price target lowered to $200 from $230 at JPMorganZoetis price target lowered to $200 from $230 at JPMorgan

Daniel Clark

Leerink Partners

$153→$152

Hold

24.66%

Upside

Reiterated

10/13/25

Leerink Partners Sticks to Their Hold Rating for Zoetis (ZTS)

Unknown Analyst

Argus Research

Not Ranked

Argus Research

$190

Buy

55.83%

Upside

Reiterated

09/09/25

Argus Research Sticks to Its Buy Rating for Zoetis (ZTS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Ryskin

Bank of America Securities

$135

Hold

10.72%

Upside

Reiterated

01/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Moderna (NASDAQ: MRNA), Zoetis (NYSE: ZTS) and Resmed (NYSE: RMD)

Andrea Alfonso

UBS

$141→$136

Hold

11.54%

Upside

Reiterated

01/29/26

Zoetis price target lowered to $136 from $141 at UBSZoetis price target lowered to $136 from $141 at UBS

David Westenberg

Piper Sandler

$190→$135

Hold

10.72%

Upside

Downgraded

01/22/26

Zoetis downgraded to Neutral from Overweight at Piper SandlerZoetis downgraded to Neutral from Overweight at Piper Sandler

Jonathan Block

Stifel Nicolaus

$140→$130

Hold

6.62%

Upside

Reiterated

01/15/26

Zoetis (ZTS) Gets a Hold from Stifel Nicolaus

Erin Wright

Morgan Stanley

$175→$160

Buy

31.22%

Upside

Reiterated

12/18/25

Zoetis price target lowered to $160 from $175 at Morgan StanleyZoetis price target lowered to $160 from $175 at Morgan Stanley

Sidharth Sahoo

HSBC

$180→$140

Buy

14.82%

Upside

Reiterated

12/10/25

Zoetis price target lowered to $140 from $180 at HSBCZoetis price target lowered to $140 from $180 at HSBC

Glen Santangelo

Barclays

$136

Hold

11.54%

Upside

Initiated

12/08/25

Zoetis initiated with an Equal Weight at BarclaysZoetis initiated with an Equal Weight at Barclays

Steve Scala

TD Cowen

$189→$150

Buy

23.02%

Upside

Reiterated

12/03/25

TD Cowen Reaffirms Their Buy Rating on Zoetis (ZTS)

Mark Massaro

BTIG

$160

Buy

31.22%

Upside

Reiterated

12/03/25

Zoetis Positioned for Long-Term Growth with Strategic Market Expansion and Innovative Product Launches

Brandon Vazquez

William Blair

Buy

―

Reiterated

12/02/25

Zoetis: Strong Innovation Pipeline and Attractive Valuation Justify Buy Rating Despite Near-Term Challenges

Steve Dechert

KeyBanc

Hold

―

Initiated

11/20/25

Zoetis initiated with a Sector Weight at KeyBancZoetis initiated with a Sector Weight at KeyBanc

Chris Schott

J.P. Morgan

$200

Buy

64.03%

Upside

Assigned

11/05/25

Zoetis price target lowered to $200 from $230 at JPMorganZoetis price target lowered to $200 from $230 at JPMorgan

Daniel Clark

Leerink Partners

$153→$152

Hold

24.66%

Upside

Reiterated

10/13/25

Leerink Partners Sticks to Their Hold Rating for Zoetis (ZTS)

Unknown Analyst

Argus Research

Not Ranked

Argus Research

$190

Buy

55.83%

Upside

Reiterated

09/09/25

Argus Research Sticks to Its Buy Rating for Zoetis (ZTS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zoetis

3 Months

xxx

Success Rate

10/17 ratings generated profit

Average Return

-2.06%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of -2.06% per trade.

1 Year

Erin WrightMorgan Stanley

Success Rate

16/24 ratings generated profit

Average Return

+8.72%

reiterated a buy rating last month

Copying Erin Wright's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.72% per trade.

2 Years

xxx

Success Rate

15/24 ratings generated profit

Average Return

+25.19%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +25.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZTS Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZTS has received 15 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. ZTS average Analyst price target in the past 3 months is 148.20.

Each month's total comprises the sum of three months' worth of ratings.

ZTS Financial Forecast

ZTS Earnings Forecast

Next quarter’s earnings estimate for ZTS is $1.40 with a range of $1.38 to $1.42. The previous quarter’s EPS was $1.70. ZTS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year ZTS has Performed in-line its overall industry.

ZTS Sales Forecast

Next quarter’s sales forecast for ZTS is $2.36B with a range of $2.34B to $2.39B. The previous quarter’s sales results were $2.40B. ZTS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year ZTS has Performed in-line its overall industry.

ZTS Stock Forecast FAQ

What is ZTS’s average 12-month price target, according to analysts?

Based on analyst ratings, Zoetis’s 12-month average price target is 148.20.

What is ZTS’s upside potential, based on the analysts’ average price target?

Zoetis has 21.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ZTS a Buy, Sell or Hold?

Zoetis has a consensus rating of Moderate Buy which is based on 6 buy ratings, 6 hold ratings and 0 sell ratings.

What is Zoetis’s price target?

The average price target for Zoetis is 148.20. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $130.00. The average price target represents 21.55% Increase from the current price of $121.93.

What do analysts say about Zoetis?

Zoetis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of ZTS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Zoetis (ZTS) Stock Forecast & Price Target

ZTS Analyst Ratings

ZTS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zoetis

ZTS Analyst Recommendation Trends

ZTS Financial Forecast

ZTS Earnings Forecast

ZTS Sales Forecast

ZTS Stock Forecast FAQ

Detailed List of Analyst Forecasts